JudySWangMD

Oncology • Sarasota, FL

Phase I Clinical Trialist, FCS/SCRI

Join to view full profile

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wang's full profile

Already have an account?

Office
Florida Cancer Specialists (SAC)
600 North Cattlemen Road, Suite 200
Sarasota, FL 34232
Phone+1 941-377-9993

Fax+1 941-343-0026
Is this information wrong?

Summary

Early phase, including first-in-human, medical oncologist and clinical trial investigator in all advanced solid tumors

Florida Cancer Specialists and Research Institute

Florida Cancer Specialists is proud to offer cancer treatment tailored to each individual, including a robust clinical trial program including Phase I.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2009 - 2012
Pennsylvania State University College of MedicineClass of 2009
Johns Hopkins UniversityBS, Biomedical Engineering, 1999 - 2003

Certifications & Licensure

FL State Medical License 2015 - 2025
MD State Medical License 2012 - 2015
PA State Medical License 2009 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer Start of enrollment: 2014 Aug 01
Completed
Phase 1
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck Start of enrollment: 2015 Aug 06
Active, not recruiting
Phase 1, Phase 2
AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors Start of enrollment: 2015 Aug 06
Completed
Phase 1
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors Start of enrollment: 2015 Nov 01
Completed
Phase 1, Phase 2
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Start of enrollment: 2015 Nov 09
Terminated
Phase 1, Phase 2
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2016 Mar 01
Active, not recruiting
Phase 1
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. Start of enrollment: 2015 Oct 28
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours Start of enrollment: 2015 Dec 28
Active, not recruiting
Phase 1
A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors Start of enrollment: 2016 Feb 01
Completed
Phase 1
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies Start of enrollment: 2016 Jan 01
Recruiting
Phase 1
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors Start of enrollment: 2016 Jun 16
Completed
Phase 1
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) Start of enrollment: 2016 Jul 08
Recruiting
Phase 1
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Start of enrollment: 2016 Sep 01
Completed
Phase 1
Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer Start of enrollment: 2016 Dec 01
Completed
Phase 1, Phase 2
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2017 Jan 06
Completed
Phase 1
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Start of enrollment: 2017 May 15
Completed
Phase 1
Study of AGEN2034 in Advanced Tumors and Cervical Cancer Start of enrollment: 2017 Apr 11
Completed
Phase 1, Phase 2
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas Start of enrollment: 2017 Jun 30
Completed
Phase 1
Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Start of enrollment: 2017 Aug 17
Completed
Phase 1, Phase 2
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Start of enrollment: 2017 Oct 25
Completed
Phase 2
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients Start of enrollment: 2017 Nov 14
Completed
Phase 1
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Start of enrollment: 2018 Apr 10
Completed
Phase 2
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors Start of enrollment: 2018 Apr 23
Recruiting
Phase 1
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer Start of enrollment: 2019 Jun 06
Completed
Phase 2
Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer Start of enrollment: 2019 Nov 14
Active, not recruiting
Phase 1
Roles: Contact
A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30
Recruiting
Phase 1, Phase 2
Roles: Contact
First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Start of enrollment: 2023 Jan 11
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong, A., Geva, R., Chung, H., Lemech, C., Miller, W., Hansen, A., Lee, J., Tsai, F., Solomon, B., Kim, T., Rolfo, C., Giranda, V., Ren, Y., Liu, F., Kandala, B.,...> ;Investigational New Drugs. 2024 Feb 1
6 citations
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.
Maria Vieito, Victor Moreno, Anna Spreafico, Irene Brana, Judy S Wang, Meir Preis, Tatiana Hernández, Sofia Genta, Aaron R Hansen, Bernard Doger, Vladimir Galvao, Laur...> ;Clinical Cancer Research. 2023 Sep 15
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma.
Erika P Hamilton, Judy S Wang, Amit M Oza, Manish R Patel, Susanna V Ulahannan, Todd Bauer, Janet L Karlix, Jorge Zeron-Medina, Giulia Fabbri, Paola Marco-Casanova, Ga...> ;Molecular Cancer Therapeutics. 2023 Oct 2
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and...
Arvind Dasari, Erika P Hamilton, Gerald S Falchook, Judy S Wang, Daneng Li, Max W Sung, Caly Chien, Shivani Nanda, Christopher Tucci, Marjo Hahka-Kemppinen, Andrew Sco...> ;Investigational New Drugs. 2023 Jun 1
1 citations
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Anastasios Stathis, Anthony W Tolcher, Judy S Wang, Daniel J Renouf, Lin-Chi Chen, Leah H Suttner, Tomoko Freshwater, Andrea L Webber, Tapan Nayak, Lillian L Siu> ;Investigational New Drugs. 2023 Jun 1
4 citations
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.
Melissa L Johnson, Judy S Wang, Gerald Falchook, Carol Greenlees, Suzanne Jones, Donald Strickland, Giulia Fabbri, Caroline Kennedy, J Elizabeth Pease, Liz Sainsbury, ...> ;British Journal of Cancer. 2023 May 1
16 citations
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
Todd Bauer, Byong Chul Cho, Rebecca Heist, Lyudmila Bazhenova, Theresa Werner, Sanjay Goel, Dong-Wan Kim, Douglas Adkins, Richard D Carvajal, Ajjai Alva, Keith Eaton, ...> ;Investigational New Drugs. 2022 Oct 1
6 citations
Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation.
Judy Wang, Patricia Martin-Romano, Philippe Cassier, Melissa Johnson, Eric Haura, Laurie Lenox, Yue Guo, Nibedita Bandyopadhyay, Michael Russell, Elizabeth Shearin, Jo...> ;The Oncologist. 2022 Jul 5
17 citations
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Joyce F. Liu, Howard A. Burris, Judy S. Wang, Lisa Barroilhet, Martin Gutierrez, Yulei Wang, Anjali Vaze, Renee Commerford, Stephanie Royer-Joo, Voleak Choeurng, Eric ...> ;Gynecologic Oncology. 2021 Oct 6
45 citations
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53.
Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald Steven Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme...> ;Clinical Cancer Research. 2021 Oct 1
25 citations
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Gerald Steven Falchook, Marc Peeters, Sylvie Rottey, Luc Dirix, Radka Obermannova, Jonathan Cohen, Ruth Perets, Ronnie Shapira Frommer, Todd M. Bauer, Judy S. Wang, Ri...> ;Investigational New Drugs. 2021 Apr 14
19 citations
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
Johann S. de Bono, Mark D. Fleming, Judy S. Wang, Richard Cathomas, Manuel Selvi Miralles, John G. Bothos, Mary Jane Hinrichs, Qu Zhang, Peng He, Marna Williams, Anton...> ;Clinical Cancer Research. 2021 Apr 1
7 citations
Reversible HER2 antibody-drug conjugate-induced ocular toxicity.
Anushree Sharma, Kamran M Riaz, Mohsain Gill, Amita Patnaik, Susanna Varkey Ulahannan, Judy S. Wang, Dan S. Gombos, Qiuqing Ang, Dragan Cicic, Gregory Bergonio, Cong Z...> ;Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie. 2021 Mar 13
4 citations
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
Kyriakos P. Papadopoulos, Nehal Lakhani, Gerald Steven Falchook, Gosia Riley, Johan Baeck, Karen S. Brown, Gilad Gordon, Lidya Le, Judy S. Wang> ;Cancer Immunology, Immunotherapy. 2021 Mar 1
41 citations
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Devalingam Mahalingam, Judy S. Wang, Erika Hamilton, John Sarantopoulos, John Nemunaitis, Garry Alan Weems, L. Carter, Xiao Hu, Marshall Schreeder, H. Jeffrey Wilkins> ;Clinical Cancer Research. 2019 Jun 15
34 citations
A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan.
Valerie Lee, Judy S. Wang, Marianna Zahurak, Elske C. Gootjes, Henk M.W. Verheul, Rose Parkinson, Zachary Kerner, Anup Sharma, Gary L. Rosner, Ana De Jesus-Acosta, Dan...> ;Clinical Cancer Research. 2018 Dec 15
94 citations
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.
Thomas S. Uldrick, Gwynn Ison, Michelle A. Rudek, Ariela Noy, Karl Schwartz, Suanna S. Bruinooge, Caroline Schenkel, Barry W. Miller, Kieron Dunleavy, Judy Sing-Zan Wa...> ;Journal of Clinical Oncology. 2017 Oct 2
35 citations
Immune Therapy in GI Malignancies: A Review
Judy Sing-Zan Wang, Kim A. Reiss, Rina Khatri, Elizabeth M. Jaffee, Daniel A. Laheru> ;Journal of Clinical Oncology. 2015 Apr 27
23 citations
Histone modifications in Rett syndrome lymphocytes: a preliminary evaluation.
Mohammed Jarrar, Judy S. Wang, Ye Jin M. Lee, Sriram Reddy, Genila Bibat, Sakkubai Naidu> ;Brain & Development. 2005 Aug 1
Join now to see all

Lectures

A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Florida Cancer Specialists & Research Institute Contributing to Rapid Advancements in Breast Cancer TreatmentDecember 13th, 2022
Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021
Sarah Cannon to Present Latest Cancer Research Insights at 2019 American Society of Clinical Oncology’s Annual MeetingMay 30th, 2019
Join now to see all